Presidio Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$244K Sell
970
-60
-6% -$12.9K 0.06% 72
2026
Q1
$224K Sell
1,030
-26
-2% -$5.77K 0.07% 64
2025
Q4
$241K Buy
1,056
+26
+3% +$5.92K 0.07% 64
2025
Q3
$238K Sell
1,030
-292
-22% -$59.5K 0.08% 60
2025
Q2
$245K Sell
1,322
-13
-1% -$2.42K 0.09% 55
2025
Q1
$280K Sell
1,335
-69
-5% -$13.4K 0.11% 52
2024
Q4
$249K Sell
1,404
-425
-23% -$78.1K 0.13% 54
2024
Q3
$361K Sell
1,829
-145
-7% -$27.1K 0.23% 46
2024
Q2
$339K Sell
1,974
-184
-9% -$30.5K 0.24% 42
2024
Q1
$393K Buy
2,158
+419
+24% +$72.2K 0.29% 30
2023
Q4
$269K Sell
1,739
-661
-28% -$96.4K 0.21% 31
2023
Q3
$358K Sell
2,400
-177
-7% -$26K 0.31% 24
2023
Q2
$347K Sell
2,577
-65
-2% -$9.53K 0.28% 29
2023
Q1
$421K Sell
2,642
-114
-4% -$17.4K 0.37% 23
2022
Q4
$445K Sell
2,756
-198
-7% -$30.4K 0.4% 20
2022
Q3
$396K Sell
2,954
-671
-19% -$96.3K 0.43% 16
2022
Q2
$555K Buy
3,625
+105
+3% +$16K 0.6% 15
2022
Q1
$571K Sell
3,520
-37
-1% -$5.38K 0.49% 16
2021
Q4
$482K Buy
+3,557
New +$420K 0.41% 15

Other funds holding ABBV

Presidio Capital Management's ABBV Position: Q2 2026 in Review

Presidio Capital Management reduced its AbbVie (ABBV) stake by 5.8% in Q2 2026, selling an estimated $12.9K and leaving 970 shares worth $244K. The position accounts for 0.06% of the portfolio, ranked #72.

Presidio Capital Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $571K in Q1 2022. 1,316 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Presidio Capital Management held 970 shares of AbbVie worth $244K as of Q2 2026.
  • Presidio Capital Management sold 60 AbbVie shares in Q2 2026, an estimated $12.9K.
  • AbbVie made up 0.06% of Presidio Capital Management's portfolio in Q2 2026, its #72 holding.
  • Presidio Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • Presidio Capital Management's AbbVie position peaked at $571K in Q1 2022.
  • 1,316 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Presidio Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.